The recent bankruptcy filing of Karyopharm Therapeutics includes a restructuring support agreement and a $55 million debtor-in-possession financing package to maintain clinical operations. This development serves as a sobering reminder of the razor-thin margins for error that currently define the
The biological hurdles of treating solid tumors with T-cell therapy are being decoded through new findings linking tumor lesion diameters to the ultimate durability of the patient response. At the current Society for Immunotherapy of Cancer Annual Meeting, researchers presented updated data
Engineering T-cells to recognize multiple antigens allows the treatment to remain effective even if some tumor cells stop expressing one of the targeted markers. For families facing a pediatric Diffuse Midline Glioma (DMG) diagnosis, the news is historically grim, as this aggressive cancer
Emerging radionuclides like Terbium-161 provide a multifaceted approach by emitting beta particles alongside Auger and conversion electrons for microscopic precision. This development represents a massive leap forward in the quest to move beyond the era of blunt-force oncology, where treatments
Statistical trends show a dramatic reduction in the number of patients required to prove efficacy when a companion diagnostic is used to identify likely responders. This transformation represents a fundamental restructuring of the cancer drug development landscape in the United States, as evidenced
The Neonatal Fc receptor has emerged as a high-value target in immunology because it plays a critical role in recycling the antibodies that sustain autoimmune activity. This shift toward complex, target-specific medicine is forcing the global pharmaceutical infrastructure to evolve beyond simple